News | August 30, 2021
Acute therapies drive overall pharma growth in July: Ind-Ra
The segment delivered strong sales growth of 20% YoY
The segment delivered strong sales growth of 20% YoY
Domestic business was up 41.9% YoY and 27.7% QoQ
Demand normalisation post the second wave contributed to the steady growth
Adjusted PAT declined 18.8% YoY
The company also plans to register the similar range of products in the neighbouring countries.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
